Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography.
A reversed-phase high-performance liquid chromatography method was developed and validated for the quantitation of pemetrexed (LY231514, ALIMTA) in human urine and plasma. Plasma samples were spiked with the internal standard lometrexol and extracted using Certify II columns. Pemetrexed was assayed in diluted urine by an external calibration method. A C8 column was used for the separation of analytes with a mobile phase composed of sodium formate buffer and acetonitrile. Between- and within-day precision and accuracy were acceptable down to the limit of quantitation of 5 ng/ml in plasma. This method was used successfully for an investigation of the disposition of pemetrexed in patients receiving 500 mg/m2 as a 10-min infusion.
Rivory
L P
LP
Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, NSW, Australia. lrivory@canc.rpa.cs.nsw.gov.au
Clarke
S J
SJ
Boyer
M
M
Bishop
J F
JF
D000970:Antineoplastic Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D005493:Folic Acid Antagonists / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D005971:Glutamates / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D006147:Guanine / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D006801:Humans; D000068437:Pemetrexed; D012680:Sensitivity and Specificity
D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine